Fig. 5

Release of IL-6 by stretch or TRPV4 agonist is regulated via ERK and p38 pathways. a E17 epithelial cells seeded on bioflex plates coated with fibronectin were preincubated for 30 min with the ERK pathway inhibitor U0126 [20 μM] or the p38 inhibitor SB203580 [20 μM] and then exposed to 20 % cyclic stretch for 48 h. Supernatants were collected and the concentration of IL-6 was analyzed by ELISA, as described in methods. Data are normalized to the cell lysate concentrations. N = 4; *p < 0.01 vs vehicle control; **p < 0.01 vs vehicle stretch. Tukey-Kramer Multiple Comparisons Test. b E17 epithelial cells seeded on fibronectin-coated plates were incubated for 48 h with the ERK pathway inhibitor U0126 [20 μM], the p38 inhibitor SB203580 [20 μM] or the JNK inhibitor SP600125 [20 μM], in the presence of DMSO (vehicle) or the TRPV4 agonist GSK1016790A [100 nM]. Supernatants were collected and the concentration of IL-6 was analyzed by ELISA, as described above. N = 3; *p < 0.05 vs negative vehicle; **p < 0.01 vs TRPV4 agonist. Tukey-Kramer Multiple Comparisons Test